IPO
Epigenomics AG announced the operational achievements plus financial results for the second quarter and the first half of 2019.
Conference call and webcast, August 07, 2019 at 3:00 pm CET, 9:00 am EST
NOXXON Pharma N.V. announced that following discussions with investors it has received letters of intent and binding commitments for long-term investment of €1 million through a private placement plus additional commitment for a future private placement.
Big Data falls short - the consulting company MAIN5 presents study “Pharma Insights 2019"
Orion Biotechnology Canada Ltd. announced that Sir Gregory Winter FRS has agreed to chair the Orion Biotechnology Scientific Advisory Board (SAB).
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Oxford Immunotec Global PLC, or the Company, a global, high-growth diagnostics company, announced second quarter 2019 financial results.
Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology
Loan reduced from US$30 million to US$11.5 million
Global Blood Therapeutics, Inc. announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the company’s common stock with a per share exercise price of $54.25 and restricted stock units for an aggregate of 69,450 shares of the company’s common stock.
PRESS RELEASES